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Abstract
Background: The classification of phase 3 trials as superiority or non-inferiority has become routine, and it is widely
accepted that there are important differences between the two types of trial in their design, analysis and interpretation.
Main text: There is a clear rationale for the superiority/non-inferiority framework in the context of regulatory trials.
The focus of our article is non-regulatory trials with a public health objective. First, using two examples from infectious
disease research, we show that the classification of superiority or non-inferiority trials is not always straightforward.
Second, we show that several arguments for different approaches to the design, analysis and interpretation of
superiority and non-inferiority trials are unconvincing when examined in detail. We consider, in particular, the
calculation of sample size (and the choice of delta or the non-inferiority margin), intention-to-treat versus per-protocol
analyses, and one-sided versus two-sided confidence intervals. We argue that the superiority/non-inferiority framework
is not just unnecessary but can have a detrimental effect, being a barrier to clear scientific thought and communication.
In particular, it places undue emphasis on tests for significance or non-inferiority at the expense of estimation. We
emphasise that these concerns apply to phase 3 non-regulatory trials in general, not just to those where the classification
of the trial as superiority or non-inferiority is ambiguous.
Conclusions: Guidelines and statistical practice should abandon the sharp division between superiority and non-
inferiority phase 3 non-regulatory trials and be more closely aligned to the clinical and public health questions that
motivate the trial.
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Background
It is widely accepted that important differences exist
between superiority and non-inferiority trials in terms
of their design, analysis and interpretation. This is
reflected in regulatory agency guidelines, CONSORT
statements on the reporting of trials and review articles
[1–5]. The European Medicines Agency states the
“pre-definition of a trial as a superiority trial, an
equivalence trial or a non-inferiority trial is necessary
for numerous reasons” [4], and one reporting guideline
asserts that non-inferiority trials present “particular
difficulties in their design, analysis, and interpretation”
[2]. Focussing on non-regulatory trials with a public
health objective, our article challenges this dogma.
Non-inferiority or superiority, which is it?
CAP-IT is a UK-based factorial randomised controlled
trial assessing the optimal dose and duration of amoxicil-
lin treatment for children with community-acquired pneu-
monia, with a primary outcome of clinical non-response
requiring re-treatment (http://www.nets.nihr.ac.uk/pro
jects/hta/138811). In original discussions, it was decided
to compare the doses of 125 mg and 250 mg, both three
times per day (although the final trial design was based on
weight-band dependent dosing). At that time, and in the
absence of any randomised evidence, the British National
Formulary specified a 250 mg dose, but surveys had
shown that the 125 mg dose was more commonly used in
clinical practice [6, 7]. This raised the dilemma of which
dose should be defined as standard and which as experi-
mental. Following conventional statistical thinking, defin-
ing 250 mg as the standard dose implies a non-inferiority
trial as the lower 125 mg dose would be unlikely to reduce
the rate of relapse; conversely, defining 125 mg as the
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standard dose implies a superiority trial. The fact that the
definition of standard versus experimental dose is arbi-
trary implies that the classification of the trial as superior-
ity or non-inferiority is also arbitrary.
Even when one treatment clearly represents the
standard intervention, the definition of the trial as
non-inferiority or superiority may be a moot point. In
the public health approach to HIV treatment, the rec-
ommended second-line regimen is a boosted protease
inhibitor in combination with two nucleoside reverse
transcriptase inhibitors (NRTIs) [8]. NRTIs are also used
in first-line regimens and concern exists that viral
cross-resistance will render them only partially effective.
Two similar trials of second-line therapy were therefore
conducted (EARNEST, SECOND-LINE) [9, 10], in which
participants were randomised to receive either clinician-
selected NRTIs or raltegravir (an integrase inhibitor).
EARNEST was conducted in sites in sub-Saharan Africa,
whereas the sites in SECOND-LINE were more diverse,
with low-, middle- and high-income countries represented
(Table 1). Although both studies regarded the NRTI
group as standard and the raltegravir group as
experimental, SECOND-LINE was defined as a non-in-
feriority trial and EARNEST as a superiority trial (Table
1). As raltegravir was more expensive at the time of the
trial than NRTIs, the EARNEST investigators argued it
would need to be shown to be more effective than
NRTIs. The SECOND-LINE investigators adopted a
more modest aim of demonstrating that raltegravir,
which has a favourable toxicity profile, was an accept-
able alternative to NRTIs that widened the range of
therapeutic options. The results and interpretation of
these two studies are discussed later.
In the remaining sections we discuss some areas where
important differences are perceived to exist between tri-
als classified as non-inferiority and those classified as su-
periority. Our points apply both to trials where the
classification is natural and those where it is not, such as
the CAP-IT trial.
Sample size and choice of non-inferiority margin
In a superiority trial, the sample size calculation is con-
ventionally based on achieving adequate power to dem-
onstrate that the relevant confidence limit for the
difference between the two treatments excludes zero, as-
suming that the experimental treatment is superior by a
given amount (‘delta’). In a non-inferiority trial, the cal-
culation is conventionally based on achieving adequate
power to demonstrate that the relevant confidence limit
excludes the specified non-inferiority margin, assuming
that the two treatments are equally effective [5, 11];
these problems are symmetrical, given these assump-
tions [11]. In the case of continuous variables, the sam-
ple size formulae are identical, provided two-sided
confidence intervals (CIs) are used. In the case of binary
variables, the formulae yield minor differences related to
the computation of standard errors; this difference can
go in either direction [12].
This raises the critical question of whether delta and
the non-inferiority margin are conceptually different
or identical. We believe they are the same, with their
meaning best captured by the term ‘smallest clinically
important difference’, which can be quantified by elicit-
ing opinions of expert clinicians and patients [13, 14].
There is no good reason why the size of this difference
(and by implication the sample size) should depend on
Table 1 Comparison of SECOND-LINE and EARNEST studies
Study SECOND-LINE [9] EARNEST [10]
Design Non-inferiority Superioritya
Investigators’ rationale Raltegravir less toxic than nucleoside
reverse transcriptase inhibitors (NRTIs),
aim to show similar efficacy
Raltegravir more expensive, aim to show better
efficacy than NRTIs
Setting 37 sites in 15 countries in 5 continents 14 sites in 5 sub-Saharan African countries
Number of subjects 588 859
Delta/non-inferiority margin 12% 10%
Primary endpoint Viral load < 200 copies/mL at 48 weeks Composite endpoint (good HIV disease control)
at 96 weeks
Frequency of primary endpoint 81% NRTI
83% raltegravir
Difference = 1.8% (95% CI –4.7 to 8.3)
60% NRTI
64% raltegravir
Difference = 4.2% (95% CI –2.4 to 10.7)
Conclusion Criterion for non-inferiority fulfilled Superiority of raltegravir not shown
Interpretation
(précised from paper Abstract)
The raltegravir regimen was easy to administer,
effective, safe and tolerable … This simple
NRTI-free treatment strategy might extend
the successful public health approach
to management of HIV
NRTIs retained substantial virologic activity without
evidence of increased toxicity, and there was no
advantage to replacing them with raltegravir
aThe EARNEST trial had a third arm – protease inhibitor monotherapy – but this is not relevant to the comparison with SECOND-LINE and is not presented here
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whether the trial is defined as superiority or
non-inferiority. In particular, it is a misconception that
non-inferiority trials need to be much larger than super-
iority trials [12]. One reason why superiority trials are
sometimes smaller is that delta is instead chosen as the
value that corresponds to the expected difference, with
optimistic values selected to reduce the sample size [14,
15]. Additionally, some non-inferiority trials define the
non-inferiority margin as a certain fraction of the effect
of the standard treatment (active control) as estimated
from previous placebo-controlled trials [1, 16]. However,
the logic of this approach has been challenged in the
regulatory setting [17]. The rationale for triangulating
results with a hypothetical placebo group is even weaker
in a health service context if offering no treatment to a
patient with the condition in question is not a viable
clinical option.
Intention-to-treat versus per-protocol analyses
In superiority trials, a rigorous primary analysis should in-
clude all randomised patients, irrespective of whether they
took study medication as randomised (intention-to-treat).
Historically, non-inferiority trials placed greater emphasis
on ‘per-protocol’ analyses, which exclude patients with
major protocol violations, including unacceptably low levels
of adherence to the study drug [18]. The rationale for this
is that including such patients dilutes the observed differ-
ence between the randomised groups and therefore
increases the chance of demonstrating non-inferiority (if
the experimental treatment is inferior). However, there is
increasing scepticism about the value of per-protocol ana-
lyses because these subvert the integrity of the randomisa-
tion and the considerable variation in interpretation of
what constitutes the per-protocol population [15, 19–21]. A
range of methods to assess the impact of non-adherence
have been developed, which can be applied equally to su-
periority and non-inferiority trials [22, 23]. The selection of
the most appropriate method depends critically on the pri-
mary research question (e.g. whether inference is intended
to apply to all patients or just to those who adhere to
the recommended treatment), requiring clear communica-
tion between clinical researchers and statisticians [22].
Significance tests versus confidence intervals (CIs)
In the SECOND-LINE trial described above, the
non-inferiority margin was specified as 12%. Further,
80.8% of patients in the NRTI (control) group and 82.6%
of patients in the raltegravir (experimental) group met the
primary endpoint (HIV RNA plasma viral load < 200 cop-
ies/mL at 48 weeks), a difference of 1.8% (95% CI –4.7 to
8.3). In the Abstract, the authors concluded that the “cri-
terion for non-inferiority was fulfilled” [2] i.e. following ad-
vice in the CONSORT guidelines to take the
non-inferiority hypothesis (margin) into account in the
interpretation of the results. However, the lower limit of
the observed CI tells us that raltegravir is inferior to
NRTIs by a margin of 4.7% at most, i.e. approximately
three-fold smaller than the pre-specified non-inferiority
margin. As inference should be based primarily on point
estimates and CIs rather than significance tests [24], the
emphasis in the results should be on the observed value of
4.7% rather than the arbitrary value of 12%. As other au-
thors have pointed out: “we will eventually come to see
that the pre-specification by the sponsor of a
non-inferiority margin does not form part of any rational
approach to analysing such trials” [25]. Finally, reports of
superiority trials usually mention ‘delta’ only in the justifi-
cation of the sample size calculation in the Methods sec-
tion, rarely playing a part in the interpretation of the
results. This is in sharp contrast with the central role of
the non-inferiority margin in the interpretation of
non-inferiority trials, and is a logical inconsistency be-
tween the two types of trial.
One-sided or two-sided confidence intervals (CIs)
A leading medical journal requires that superiority trials
present two-sided CIs but that non-inferiority trials
present one-sided CIs [26]. This is based on the dubi-
ous argument that “a non-inferiority trial only aims to
demonstrate non-inferiority and does not aim to distin-
guish non-inferiority from superiority” [26]. However,
regulatory agencies do not exclude the possibility of
switching between superiority and non-inferiority [4],
and it makes no sense to ignore evidence on superiority
if a trial produces such evidence, even if this outcome
was not anticipated. A recent paper argues that a clear
distinction should be made between statistical and clin-
ical superiority, along with consistent presentation of
two-sided CIs [11].
Same results, different conclusions
The SECOND-LINE and EARNEST trials both found no
material difference between the two randomised treat-
ment strategies in terms of the study primary endpoints
(Table 1). The investigators of EARNEST (the superior-
ity trial) interpreted their results as evidence supporting
the use of NRTIs in second-line regimens; the investiga-
tors of SECOND-LINE (the non-inferiority trial) con-
cluded that raltegravir was an acceptable alternative to
NRTIs in a second-line regimen. These conclusions are
both ‘correct’ within the particular statistical framework
chosen by the trial investigators. The fact that the con-
clusions are contradictory, despite a partial geographical
overlap in the location of trial sites, raises concerns
about the framework itself. While it is not unreasonable
for two scientists to interpret the same data differently,
the pre-definition of a trial as superiority or
non-inferiority tends to impel a certain narrative
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influenced by the results of tests of significance or
non-inferiority.
Decision-making
Non-inferiority trials were originally developed in the set-
ting of drug approval, where regulatory agencies have to
make a binary decision – either to licence or to not licence
the experimental treatment. To ensure that the process is
transparent and explicit, the agencies justifiably require
that the study sponsors produce detailed study protocols,
including pre-specification of the non-inferiority margin.
In contrast, the main objective of non-licencing trials is to
publish information that allows other bodies (commis-
sioners of health services, producers of clinical guidelines,
etc.) to make considered decisions about which treatments
should be funded or recommended. These decisions are
complex and need to consider issues such as cost, adverse
drug effects and quality of life, in addition to clinical effi-
cacy [12]. Ideally, decision analysis models should be
employed based on a synthesis of all relevant evidence.
Evidence syntheses do not treat superiority and
non-inferiority trials differently, nor do they consider
whether a trial delivered a significant or non-significant
result. As pointed out by Claxton: “the historical accident
that dictates which of the alternatives is regarded as
current practice is irrelevant” [27].
Conclusions
Our two examples highlight that the classification of trials
as superiority or non-inferiority is sometimes arbitrary, par-
ticularly when the classification of treatment groups as
standard or experimental is not straightforward. This would
not matter much if the distinction was only one of termin-
ology, but the received wisdom is that this classification has
an important bearing on how a trial is designed, analysed
and interpreted. However, we have shown that the argu-
ments in support of this belief are weak and contend that
the superiority/non-inferiority framework can act as a bar-
rier to clear scientific thought and communication. In par-
ticular, it places undue emphasis on tests for significance or
non-inferiority at the expense of estimation. We stress that
these concerns apply to phase 3 non-regulatory trials in
general, not just to those where the classification is ambigu-
ous. Guidelines and statistical practice should abandon the
sharp division between superiority and non-inferiority
phase 3 non-regulatory trials, and should instead be more
closely aligned to the clinical and public health questions
that motivate the trial.
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